Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Neurocrine Biosciences Inc (NBIX)  
$141.91 0.09 (0.06%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 93,430,000
Market Cap: 13.26(B)
Last Volume: 670,978 Avg Vol: 808,349
52 Week Range: $89.53 - $143.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  946
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Neurocrine Biosciences is applying its capabilities into neuroscience to develop medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Co.'s commercially available medicines include INGREZZA®, which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules); and ONGENTYS®, which is a once-daily, peripherally acting Catechol-O-methyltransferase inhibitor utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson's disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 275,180 771,010 813,558 1,280,765
Total Sell Value $37,779,030 $101,803,598 $106,435,205 $158,397,673
Total People Sold 5 15 15 17
Total Sell Transactions 17 70 85 154
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 807
  Page 15 of 33  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Roberts Eiry Chief Medical Officer   •       –      –    2020-02-07 4 AS $103.31 $167,675 D/D (1,623) 7,452 16%     
   Lippoldt Darin Chief Legal Officer   •       –      –    2020-02-07 4 AS $103.32 $157,247 D/D (1,522) 24,124 16%     
   Gano Kyle Chief Business Development Off   •       –      –    2020-02-07 4 AS $103.33 $167,710 D/D (1,623) 91,975 16%     
   Gorman Kevin Charles Chief Executive Officer   •       •      –    2020-02-07 4 AS $103.35 $335,696 D/D (3,248) 432,357 16%     
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-02-07 4 AS $103.33 $167,702 D/D (1,623) 146,641 16%     
   Benevich Eric Chief Commercial Officer   •       –      –    2020-02-06 4 AS $101.48 $141,561 D/D (1,395) 18,262 16%     
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-02-06 4 AS $101.56 $141,670 D/D (1,395) 145,180 16%     
   Lippoldt Darin Chief Legal Officer   •       –      –    2020-02-06 4 AS $101.47 $121,556 D/D (1,198) 22,755 16%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-02-06 4 AS $101.52 $151,258 D/D (1,490) 22,287 16%     
   Gorman Kevin Charles Chief Executive Officer   •       •      –    2020-02-06 4 AS $101.56 $441,068 D/D (4,343) 429,436 16%     
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2020-02-06 4 AS $101.44 $81,456 D/D (803) 110,587 16%     
   Gano Kyle Chief Business Development Off   •       –      –    2020-02-06 4 AS $101.41 $101,413 D/D (1,000) 90,514 16%     
   Benevich Eric Chief Commercial Officer   •       –      –    2020-02-05 4 AS $102.90 $201,311 D/D (1,954) 17,007 15%     
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-02-05 4 AS $103.00 $210,779 D/D (2,046) 143,925 15%     
   Lippoldt Darin Chief Legal Officer   •       –      –    2020-02-05 4 AS $102.88 $180,207 D/D (1,750) 21,678 15%     
   Cooke Julie Chief Human Resources Officer   •       –      –    2020-02-05 4 AS $103.17 $62,417 D/D (605) 3,821 15%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-02-05 4 AS $103.03 $200,733 D/D (1,948) 21,127 15%     
   Gorman Kevin Charles Chief Executive Officer   •       •      –    2020-02-05 4 AS $103.08 $561,726 D/D (5,449) 425,529 15%     
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2020-02-05 4 AS $103.15 $166,894 D/D (1,618) 109,865 15%     
   Gano Kyle Chief Business Development Off   •       –      –    2020-02-05 4 AS $103.01 $380,262 D/D (3,690) 89,614 15%     
   Roberts Eiry Chief Medical Officer   •       –      –    2020-01-08 4 AS $111.11 $292,445 D/D (2,632) 5,991 2%     
   Abernethy Matt Chief Financial Officer   •       –      –    2019-12-02 4 AS $116.33 $191,360 D/D (1,645) 3,876     -
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2019-11-18 4 AS $115.98 $579,900 D/D (5,000) 108,408     -
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2019-11-18 4 OE $35.99 $179,950 D/D 5,000 113,408     -
   Lippoldt Darin Chief Legal Officer   •       –      –    2019-11-08 4 AS $110.00 $1,100,057 D/D (10,000) 20,103     -
  807 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 15 of 33
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us